McIlleron H - Search Results

1

Special populations and pharmacogenetic issues in tuberculosis drug development and clinical research.

McIlleron H, Abdel-Rahman S, Dave JA, Blockman M, Owen A. McIlleron H, et al. J Infect Dis. 2015 Jun 15;211 Suppl 3(Suppl 3):S115-25. doi: 10.1093/infdis/jiu600. J Infect Dis. 2015. PMID: 26009615 Free PMC article. Review.

2

Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome.

McIlleron H, Meintjes G, Burman WJ, Maartens G. McIlleron H, et al. J Infect Dis. 2007 Aug 15;196 Suppl 1:S63-75. doi: 10.1086/518655. J Infect Dis. 2007. PMID: 17624828 Review.

3

Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis.

Ren Y, Nuttall JJ, Eley BS, Meyers TM, Smith PJ, Maartens G, McIlleron HM. Ren Y, et al. J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):439-43. doi: 10.1097/QAI.0b013e31819c33a3. J Acquir Immune Defic Syndr. 2009. PMID: 19223781 Clinical Trial.

4

Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines.

McIlleron H, Willemse M, Werely CJ, Hussey GD, Schaaf HS, Smith PJ, Donald PR. McIlleron H, et al. Clin Infect Dis. 2009 Jun 1;48(11):1547-53. doi: 10.1086/598192. Clin Infect Dis. 2009. PMID: 19392636

5

Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors.

Pepper DJ, Marais S, Wilkinson RJ, Bhaijee F, Maartens G, McIlleron H, De Azevedo V, Cox H, McDermid C, Sokhela S, Patel J, Meintjes G. Pepper DJ, et al. Among authors: mcilleron h. BMC Infect Dis. 2010 Mar 30;10:83. doi: 10.1186/1471-2334-10-83. BMC Infect Dis. 2010. PMID: 20353569 Free PMC article.

6

Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional study.

Sinxadi PZ, van der Walt JS, McIlleron HM, Badri M, Smith PJ, Dave JA, Levitt NS, Maartens G. Sinxadi PZ, et al. AIDS Res Ther. 2010 Jul 14;7:23. doi: 10.1186/1742-6405-7-23. AIDS Res Ther. 2010. PMID: 20630064 Free PMC article.

7

Pyrazinamide plasma concentrations in young children with tuberculosis.

McIlleron H, Willemse M, Schaaf HS, Smith PJ, Donald PR. McIlleron H, et al. Pediatr Infect Dis J. 2011 Mar;30(3):262-5. doi: 10.1097/inf.0b013e3181fbefe1. Pediatr Infect Dis J. 2011. PMID: 21416694

8

Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis.

McIlleron H, Ren Y, Nuttall J, Fairlie L, Rabie H, Cotton M, Eley B, Meyers T, Smith PJ, Merry C, Maartens G. McIlleron H, et al. Antivir Ther. 2011;16(3):417-21. doi: 10.3851/IMP1757. Antivir Ther. 2011. PMID: 21555825

9

The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.

Chigutsa E, Visser ME, Swart EC, Denti P, Pushpakom S, Egan D, Holford NH, Smith PJ, Maartens G, Owen A, McIlleron H. Chigutsa E, et al. Among authors: mcilleron h. Antimicrob Agents Chemother. 2011 Sep;55(9):4122-7. doi: 10.1128/AAC.01833-10. Epub 2011 Jun 27. Antimicrob Agents Chemother. 2011. PMID: 21709081 Free PMC article.

10

The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy.

Decloedt EH, Maartens G, Smith P, Merry C, Bango F, McIlleron H. Decloedt EH, et al. Among authors: mcilleron h. PLoS One. 2012;7(3):e32173. doi: 10.1371/journal.pone.0032173. Epub 2012 Mar 7. PLoS One. 2012. PMID: 22412856 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

204 results

Search Page